Interventional, Randomized, Open-label, Three-group, Two-sequence Crossover, Single-dose, Bioequivalence Study of Lu AF35700 in Healthy Subjects Comparing the 5, 10 and 20 mg Commercial Tablet (Test) to the 5, 10 and 20 mg Clinical Tablet (Reference)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs LU AF-35700 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 28 Nov 2018 Status changed from recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 13 Jul 2018 to 5 Oct 2018.
- 23 Aug 2018 Planned primary completion date changed from 20 Jun 2018 to 5 Oct 2018.